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IN anaesthetized, paralysed, ventilated pigs the ability of
inhaled nitric oxide (80 ppm in 02) to reduce the
haemodynamic and respiratory effects of endothelin-1
administration (200 pmol/kg, i.v.) was evaluated. The
mechanical properties of the respiratory system were
evaluated by the rapid airway occlusion technique. The
overall respiratory resistance, the interrupter resistance
and the additional resistance that reflects the viscoelastic
properties of tissues and the inequality of the time con-
stant within the system were also evaluated. The results
show that inhaled nitric oxide can act as a selective
pulmonary vasodilator and as a bronchodilator to coun-
teract the vasoconstrictor and bronchoconstrictor activ-
ity of endothelin-1. In the pig, nitric oxide inhaled at 80
ppm for 6 mitt reduced the changes in respiratory-, inter-
rupter- and additional resistance due to endothelin-1 ad-
ministration without significantly changing the static and
dynamic elastance of the respiratory system.
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Introduction
There have been reports concerning mediators
released from endothelium which modulate the con-
traction of the vascular and non-vascular smooth
muscles. These mediators include some arachidonic
acid metabolites (PgI2, TXA,), the vasoconstrictor
peptides (endothelin) and endothelium-dependent
releasing factor (EDRF), recently identified as nitric
oxide (NO).>7 Experiments performed in vivo in the
guinea-pig or in vitro on isolated guinea-pig and
rabbit airway segments showed that endothelin-1
(ET-1), a peptide of endothelin family, induces
bronchoconstriction,s-l The localization of ET-l-like
immunoreactivity in the airway epithelium of rats and
mice, associated with the activity of the peptide on
the tracheobronchial tree indicate that ET-1 has a role
in modulation of bronchial tone.,*" Nitric oxide, the
new potent endothelial vasodilator factor, recently
discovered by Furchgott and Zadawski, inhibits the
contraction in vitro of tracheal smooth muscles from
man and the guinea-pig,1-15 but has no effect on
canine bronchial smooth muscle. 16 Even though its
effects on bronchial smooth muscles differ for differ-
ent muscles, nitric oxide is considered to be a media-
tor of a nonadrenergic noncholinergic (NANC) sys-
tem regulating bronchial tone.3a5 It has been shown
in animal and human studies that inhalation of NO
attenuates the hypoxic pulmonary vasoconstriction
response and tromboxane mediated pulmonary vas-
cular contraction. 17-9
Therefore, an imbalance of the ratio of ET-1 to NO
could contribute to the appearance of
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bronchospastic and pulmonary hypertensive disor-
ders. The authors wished to see whether or not
inhaled NO, diffusing throughout the airway epithe-
lium, might act directly on underlying smooth mus-
cles to counteract the ET-1 bronchoconstrictor re-
sponse.
In this study the ability of inhaled NO to reduce the
effects of ET-1 on the pulmonary and systemic vas-
cular bed and on the elastance and resistances of
respiratory system in anaesthetized, paralysed, me-
chanically ventilated pigs, has been evaluated.
Materials and Methods
Six Large White pigs, of either sex, weighing 20 + 2
(S.E.) kg, were used. They were sedated with 1%
propionylpromazine hydrochloride (0.05 ml/kg i.m.)
and anaesthetized with 15 mg/kg thiopental-sodium
injected into the auricular vein, followed by infusion,
drop by drop of 9 mg/kg/h. The animals were tied
in the supine position on a heated operating table,
tracheostomized, paralysed with pancuronium bro-
mide (0.2 mg/kg, i.v.) and ventilated mechanically
(Servoventilator Siemens 900 C). When necessary,
additional paralysing drug (pancuronium bromide,
0.2 mg/kg, i.v.) was administered during the exper-
iments.
Airflow () was measured by a pneumotachograph
(Fleisch N.2) connected to a differential pressure
transducer (Statham PM15,10846) and tidal volume
(Vt) was obtained by electronic integration of .
Tracheal pressure (Ptr) was measured at the side port
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of the tracheal cannula by a differential pressure
transducer (Statham PM15,15299). A Swan Ganz cath-
eter (5F) was inserted into the pulmonary artery to
monitor mean pulmonary arterial pressure (MPAP).
The right femoral artery was cannulated with a
polyethylene catheter to monitor mean arterial blood
pressure (MAP). Systemic and pulmonary arterial
pressure were recorded by connecting the catheters
to a fluid-filled capacitance manometer (Bell &
Howell 4-422). Haemoglobin, methaemoglobin and
blood gas analyses were performed on an arterial
blood sample (I.L.282 CO-Oximeter and Blood Gas
Analyzer I.L.282). All parameters were recorded on a
pen recorder (Nec San-ei Instruments Polygraph mod
8K40). The heart rate was evaluated by polygraph
trace. "
and Ptr were also recorded on an FM mag-
netic tape recorder (Racal Store) and, after sampling
at 2 000 Hz by a 12-bit analogue-to-digital converter,
analysed on an AST personal computer.
After evaluation of control values obtained when
the animals were breathing air through the
Servoventilator, ET-1 was administered through the
Swan Ganz catheter at a dose of 200 pmol/kg. At the
peak of ET-1 dependent vascular and respiratory
effects (about 10 min), nitric oxide (NO) was inhaled.
NO was administered through Servoventilator for 6
min. The inspired gas was a precise mixture of
oxygen and nitrogen immediately diluted with NO to
produce the desired concentration of inspired NO
(80 ppm). With volumetrically calibrated flowmeters,
NO in the bag (mixture of 235 ppm NO in pure N2)
was substituted for pure N,. to give the desired
concentration of inspired NO at a concentration of
inspired oxygen (FiO,) of 0.6-0.7. We used 60-70%
oxygen to avoid hypoxic vasoconstriction.
Procedure and data analysis: The baseline ventilator
settings were a fixed inflation volume (AV) of
0.2 + 0.01 (S.E.) and a fixed inspiratory flow of
0.25 + 0.01 (S.E.) 1/s. Respiratory frequency was
24 + 1 (S.E.) breaths/min. The ratio of inspiratory
time to total breathing cycle duration was 0.33 + 0.01
(S.E.) The baseline settings were kept constant
throughout the experiment for all animals. To reduce
the effects of the compliance of the system on the
mechanics measurements, a fixed length standard
low-compliance tube was used (2 cm i.d., 60 cm
long) to connect the animal to the ventilator and the
humidifier was omitted from the inspiratory line. The
equipment flow resistance was 0.5 cm H,.O/l/s and
the equipment dead space was 29.5 ml. Respirato
mechanics values were assessed by the constant V
end-inspiratory occlusion method.2 Briefly, main-
taining flow at its baseline value, single breath airway
occlusions were performed randomly at inflation
volumes between 0.05 and 0.2 1. Each occlusion was
followed by a rapid initial drop in tracheal pressure
(Pmax-Pl) and was maintained until the apparent
plateau (P2) was achieved (5-6 s). The plateau rep-
resented the end-inspiratory elastic recoil pressure.
The contribution of reduction in pressure during this
period to continuing gas exchange is negligible. The
initial tracheal pressure drop from Pmax tO P1, divided
by the immediately preceding steady , provided the
interrupter resistance of the total respiratory system
(Rint). Dividing P1-P2 by before the occlusion, we
obtained the additional effective resistance of the
respiratory system (AR) due to the viscoelastic prop-
erties of the thoracic tissues and the time constant
inequalities within the system. The total resistance of
the respiratory system (Rmax) was obtained by divid-
ing Praax-P,. by the pre-occlusion flow. The static
elastance of respiratory system (Est) was obtained by
dividing P2 by the inspiratory volume, while the
dynamic elastance (Eyn) was obtained by dividing P
by pre-occlusion Vt.
Statistical analysis: Regression analysis was done by
the least-squares method. The control values were
compared with those obtained at the peak effect of
ET-1 administration or after NO inhalation, using the
Student two-tailed t-test, p < 0.05 was accepted as
statistically significant. Values are means + S.E.
Results
Administration of ET-1 increased the mean pul-
monary arterial pressure (from 18.88 + 1.88 (S.E.) to
27.52 + 3.49 (S.E.) mmHg) and the mean arterial
pressure (from 113.06 + 10.42 (S.E.) to 133.07 + 10.87
(S.E.) mmHg), without a change in heart rate (HR).
Inhalation of NO at the peak effect of ET-1 adminis-
tration (about 10 min) significantly decreased MPAP
(from 27.52+3.43 (S.E.) to 16.95+3.53 (S.E.)
mmHg), without modifying systemic arterial pressure
or heart rate. ET-1 administration and inhaled NO did
not change haemoglobin, methaemoglobin or blood
gas values (data not reported).
The a and b constants (intercept and slope) of the
regression lines of Rmx, Rint and AR with AV in control
condition, after ET-1 administration and after NO
inhalation are given in Table 1. Figure 1 illustrates the
mean relationships (+ S.E.) between the respiratory
resistances and AV. ET-1 administration did not alter
the positive correlation of Rmax, Rin and AR with AV,
but significantly increased the slope of the AR rela-
tionship. Inhalation of NO at the time of the peak
effect of ET-1 administration (about 10 min) counter-
balanced the peptide’s effects on respiratory
resistances, significantly changing the intercept and
slope of tmax, Rin and AR regression lines with AV
(Table 1, Fig. 1).
Fig. 2 shows the mean relationships + S.E. for Es or
Ey to AV in control conditions, after ET-1 adminis-
tration and after NO inhalation. The data show that
ET-1 did not alter the negative correlation of static
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Table 1. Linear regressions obtained between the overall respiratory resistances (Rnax), interrupter resistance (R,t) and
additional resistance (AR) and inflation volume (AV, I).
Pig Rma
(reference
no.) Ctr ET-1 NO
a b p a b p a b p
4.93 85.80 0.001 5.31 91.41 0.010 8.62 32.52 NS
2 6.10 54.25 0.001 4.41 82.71 0.001 5.87 67.12 0.001
3 1.32 90.40 0.050 1.65 91.65 0.001 2.13 78.06 0.001
4 2.00 62.19 0.001 2.41 94.51 0.001 6.46 67.61 0.001
5 5.39 71.30 0.001 7.15 68.95 0.001 9.29 54.50 0.001
6 14.55 39.29 0.050 12.84 51.97 0.001 14.22 34.41 0.005
Mean 5.72 67.21 5.63 80.20 7.77** 55.70**
S.E. 2.33 27.44 2.30 32.74 3.17 22.74
Pig Rin
(reference
no.) Ctr ET-1 NO
a b p a b p a b p
3.69 34.92 0.001 5.24 29.76 0.001 6.41 8.10 NS
2 3.47 24.39 0.005 2.29 34.86 0.001 3.52 25.12 0.003
3 1.94 27.61 0.001 1.96 32.16 0.001 2.56 23.16 0.010
4 2.16 20.40 0.003 2.64 25.81 0.050 3.94 18.19 0.001
5 4.02 31.96 0.001 4.95 23.28 0.002 5.48 22.16 0.001
6 13.63 14.24 0.001 12.85 17.72 0.001 13.77 0.76 NS
Mean 4.82 25.59 4.99 27.27 5.95** 16.25**
S.E. 1.97 10.45 2.04 11.13 2.43 6.63
Pig AR
(reference
no.) Ctr ET-1 NO
a b p a b p a b p
1.24 50.88 0.001 0.06 61.65 0.050 2.23 24.41 NS
2 2.63 29.86 0.007 2.12 47.85 0.007 2.34 41.99 0.007
3 -0.62 62.79 0.001 -0.30 59.53 0.001 -0.43 54.91 0.001
4 -0.15 41.78 0.002 -0.23 68.69 0.002 2.52 49.41 0.001
5 1.36 39.34 0.001 2.19 45.66 0.001 3.80 32.34 0.002
6 0.92 25.04 0.001 -0.01 34.25 0.001 0.45 33.65 0.001
Mean 0.90 41.62 0.64 52.94* 1.82** 39.45"
S.E. 0.37 16.99 0.26 21.61 0.74 16.11
Intercept (a, cmH10.l-l.s), slope (bcmH20.
-1 .s) and pof the curves. Ctr controt’, ET-1 endothetin-1 administration; NO nitric
oxide inhalation. The asterisks (*) indicate statistically significant differences of Ctr vs. ET-1 (p < 0.05); (*3 indicate statistically
significant differences of ET-1 vs. NO (p < 0.05).
and dynamic elastance with inflation volume but,
even though not significantly, increased these values,
especially when the respiratory system was inflated
with smaller volumes. Inhalation of NO reduced the
effects of ET-1 on static and dynamic elastance.
Discussion
This study shows that inhaled nitric oxide can act
as a selective local pulmonary vasodilator arid as a
bronchodilator. In the pig, inhaled NO reduces the
pulmonary hypertension and the bronchoconstrictor
effects of ET-1.
In spontaneously breathing lambs and in human
volunteers with induced hypoxia, Frostell et al. 17,18
demonstrated that inhalation of NO at small doses
(5-80 ppm) reversed hypoxic pulmonary vasocon-
striction, without causing systemic vasodilatation,
and attenuated thromboxane-mediated pulmonary
vascular contraction. Consequently, it has been sug-
gested that inhaled NO might be an important tool
for reducing pulmonary hypertension in severe car-
diac pulmonary diseases.
21 As in previous studies,7a8
the present results show that in the pig, too, inhaled
NO has a selective vasodilator activity in the lung,
without affecting systemic pressure. This local re-
sponse is probably due to its rapid reaction with
haemoglobin to form methaemoglobin or to its con-
version into nitrites and nitrates. 4,22,23 The rapid inac-
tivation prevents the systemic vascular relaxing effect
of NO, without altering the systemic vasoconstrictor
activity of endothelin-1.
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FIG. 1. Average +/- S.E. (n= 6) relationships to AV of overall respiratory
resistance (R,ax) in Panel A; interrupter resistance (Rnt) in Panel B; and
additional resistance (AR) in Panel C of the respiratory system. Ctr, control,
(); ET-1 bolus administration, ); NO inhalation, ). The aster-
isks (*) indicate statistically significant differences of Ctr vs. ET-1 (p < 0.05);
(.) indicate statistically significant differences of ET-1 vs. NO (p < 0.05).
The absence of significant changes in met-
haemoglobin, in our pigs, suggests that NO has
modest toxicity when inhaled at low concentrations.
As found by Frostell et al. 17 for spontaneously breath-
ing lambs, inhalation of 80 ppm NO at FiO of 0.6-
0.7 caused a minimal oxidation of nitric oxide to
At high concentrations NO,. causes pulmonary injury
and bronchoconstriction. 24 We did not measure
plasma levels of NO,. and, although it is not possible
to exclude the possibility that it might act on airway
smooth muscles, our results show that inhalation of
NO causes bronchodilatation, reducing the effects of
ET-1 on respiratory resistances and elastance, relax-
ing precontracted airway smooth muscles.
The ratio of released ET-1 to NO regulates the
vascular tone25 and impairment of the ratio of produc-
tion of these endothelium-derived factors could con-
tribute to pulmonary hypertension associated with
bronchoconstriction.
It has also been proposed that the mediators re-
leased by airway epithelium are important for regu-
lation of bronchial tone. The epithelial lining of the
airway produces an epithelium-derived relaxing fac-
tor (EpDRF),26 considered to be similar to NO, and
parenchyma lung is directly involved in release and
clearance of ET-1.11,12 The removal of epithelium
induces hyperreactivity of the canine airway strip and
changes the responsiveness of porcine bronchial
smooth muscles. ,.7,28 It is also known that the mucus
on the epithelial layer surface, binding oxygen radi-
cals, acts as a limiting barrier for diffusion of NO.
Even if this effect was present in our experiments, the
observed reduction of ET-l-dependent vascular and
respiratory effects shows that nitric oxide can diffuse
throughout the epithelial layer. Even though in the
pig ET-1 does not have a potent bronchoconstrictor
activity, the inhaled NO relaxes smooth muscles and
reduces respiratory resistances (Rmax, Rint, AR). The
endogenous release of nitric oxide due to peptide
administration probably counteracts the true
bronchoconstrictor activity of ET-1. Nitric oxide activ-
ity probably occurs only when the smooth muscles
are precontracted because, as suggested by Dimori et
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al., 29 inhaled nitric oxide does not change normal
bronchomotor tone.
It is known that there is an additional neural
regulatory system of bronchial tone, besides the
adrenergic and cholinergic system.
3,31 The mediators
of this non-adrenergic non-cholinergic (NANC) sys-
tem have not yet been identified although there is an
increasing suspicion that NO is involved. Bronchial
contraction due to methacholine32 or electric field
stimulation, which is known to act via the NANC
system, is counterbalanced by NO. 33
Recent studies have shown that when NO is added
to tracheal and bronchial rings the tracheal rings relax
whereas the bronchial rings are less dilated. 34 Its
selective activity may have influenced the
bronchodilating response observed in this study.
Pison et al. 35 suggested that NO redistributes blood
flow to the better-ventilated alveoli. This activity,
together with reduction of respiratory resistances and
elastance, may favour mechanical respiratory func-
tion and gas exchange. Also if our results show a
modest activity of NO on ET-1 dependent
bronchoconstriction they suggest therefore that in-
haled nitric oxide may play an important therapeutic
role in hypertensive and obstructive lung disease.
In summary, this study suggests that NO, when
inhaled in small doses, does not have any significant
toxicity, but has selective local pulmonary
vasodilator and bronchodilator activity. Conse-
quently, inhaled NO might well serve as an adjuvant
therapy to existing treatment for bronchospastic and
pulmonary hypertensive disorders, especially when
they are caused by an imbalance of the ratio of
endothelin-1 to nitric oxide.
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